As COVID-19 continues to spread, ESMO encourages the oncology community to run collaborative initiatives to answer important questions: How to manage cancer care in patients with suspected or confirmed COVID-19? How to identify risk factors and outcomes associated to the infection? How is COVID-19 impacting on oncology professionals? And others which become relevant as the situation evolves.
Impact of COVID-19 on Cancer Service Delivery - Follow Up Survey
ESMO is pleased to collaborate with the University of Melbourne and Peter MacCallum Cancer Centre on this follow up survey designed to further explore changes in the clinical management of cancer patients due to the COVID-19 pandemic. The survey is open to medical oncologists, radiation oncologists, surgical oncologists and trainees in these fields.
ESMO Resilience Task Force Survey Series: COVID-19 – What is your current “normal”?
The ESMO Resilience Task Force will carry out a series of global collaboration surveys to evaluate how oncologists and other oncology professionals across the world are affected by the challenges posed by the COVID-19 pandemic, assessing changes to routine practices, well-being and current levels of support.
The surveys will cover relevant issues as the COVID-19 pandemic evolves and the longer-term impact across countries.
The first survey "How are you reacting to the COVID-19 outbreak?" is now closed – see some preliminary results.
The second survey focuses on the current ‘normal’ for oncology professionals as a result of the COVID-19 pandemic. This is an opportunity to assess the longer-term impact of COVID-19 across global regions.
The impact of COVID-19 on social media use and virtual meetings
To address the needs of oncology professionals during the COVID-19 pandemic, ESMO has launched a survey to understand the role of social media and virtual meetings in sharing information during this time.
This survey, a collaboration between ESMO Leaders Generation Programme Alumni Members, the ESMO Social Media Working Group and the OncoAlert Network, will help ESMO to understand how you have been using social media and virtual meetings since the start of the COVID-19 outbreak and will provide relevant information about the future of these areas in oncology.
Is the COVID-19 pandemic exacerbating gender inequalities in oncology?
This is the question the ESMO Women for Oncology Committee is addressing in a new COVID-19 and gender survey about how the pandemic is affecting work and home life of oncology professionals.
Only by identifying and addressing current issues now can we develop appropriate response strategies for the near and long-term future. That is why today we are asking for your help to assess the impact of the COVID-19 pandemic on the gender gap by taking our survey. The survey is anonymous and will take less than 10 minutes to complete.
This survey is no longer active.
ESMO COVID-19 and CAncer REgistry Protocol
By pooling real-world data, the ESMOCoCARE Registry aims to quickly gather data and information about treatment approaches specifically focusing on the impact of SARS-CoV-2 on cancer patients who are suspected or confirmed to have the novel coronavirus disease (COVID19).
A better understanding of the unique effects of COVID-19 on patients with cancer and cancer survivors will allow to disseminate information and guidance for this particularly vulnerable group of patients and, ultimately, to propose approaches to mitigate the risks related to COVID-19 in cancer patients.
EHA initiative in collaboration with ESMO
The most urgent question and almost impossible to answer: which therapies should be administered/continued and which should be deferred/stopped? A survey amongst experts in their respective fields to get a better understanding of the risks. The survey will close on 27 April 2020.
TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) registry for thoracic cancers
A global consortium designed to gather information on patients with thoracic cancer infected with COVID-19 regardless of therapies administered. The initiative currently involves more than 100 investigators worldwide.
Main contact: Jennifer Whisenant, Vanderbilt-Ingram Cancer Center, Nashville, US. - E-Mail